Targeted Radiotherapy
About us
- Team
- Contact
- Directions
News
Careers
Search
Menu Menu

Blog - Latest News

You are here: Home1 / 20192 / Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program...

23. September 2019/by imken

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Share this entry

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png 0 0 imken https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png imken2019-09-23 12:31:552019-10-11 15:44:33Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Imprint
Data privacy statement

3B Pharmaceuticals GmbH
Magnusstraße 11
D-12489 Berlin
Tel: +49 (0)30 / 63 92 - 43 17
Fax: +49 (0)30 / 63 92 - 43 16
info@3b-pharma.com

Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaborati...Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing...

Scroll to top